

# IFOM ETS - KYOTO UNIVERSITY JOINT MINI-SYMPOSIUM

ミニシンポジウム開催のお知らせ



**November 9, 2022**  
**13:30 - 15:30**



**医学研究科B棟 3階基礎第一講堂**  
**Main Auditorium, Medical B-building 3rd Floor**

イタリア分子癌研究所(IFOM ETS)は基礎研究から臨床研究までをカバーする世界でも有数のがん研究所で、医学研究科内にIFOM-KU 国際共同ラボ(オンサイトラボ)を設置しています。今般、同研究所からの使節団を迎えミニシンポジウムを開催いたします。ふるってご参加ください。

## Program:

**13:30- Opening remarks**


**Michiyuki Matsuda**, Kyoto Univ.  
Coordinator of IFOM-KU JRL

**13:35- Mechanism of mitotic telomere deprotection**



**Makoto Hayashi**, IFOM ETS/ Kyoto Univ.  
Junior PI (Chromosome Instabilities, IFOM-KU JRL)

**14:00- B cell receptor control of lymphoma immune surveillance**



**Stefano Casola**, IFOM ETS  
PI (Genetics of B Cells and Lymphomas Lab)

The Casola laboratory applies in vivo and ex vivo functional genomics approaches to mouse and human normal and cancerous B cells, to unveil key genetic and epigenetic determinants controlling B cell differentiation and malignant transformation, and to define their role in lymphoma therapy resistance, or as cancer vulnerability targets.

**14:45- Inactivation of DNA repair and high dose Vitamin C boost cancer immunotherapy**



**Alberto Bardelli**, IFOM ETS  
PI (Genomics of Cancer and Targeted Therapies Lab)  
Scientific Director of IFOM ETS

The Bardelli lab pioneered the combined use of genomics, patients' avatars to accurately predict tumor's response and resistance to targeted agents. He identified novel biological mechanisms of resistance and sensitivity to cancer therapies, defined how deficiencies in DNA repair pathways lead to tumor immune surveillance and pioneered the use of liquid biopsies to track cancer evolution.